Stockreport

Keros Therapeutics Reports Third Quarter 2025 Financial Results

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focu [Read more]